Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127098772 | 12709877 | 2 | F | 20160822 | 20160902 | 20160902 | EXP | ALCN2016US006082 | SANDOZ | CHAM A.; BANSAL M.; BANDA H.K.; KWON Y.; TLUCEK P.S.; BASSUK A.G.; TSANG S.H.; SOBOL W.M.; FOLK J.C.; YEH S.; MAHAJAN V.B. SECONDARY GLAUCOMA IN CAPN5 ASSOCAITED NEOVASCULAR INFALMMATORY VITREORETINOPATHY. CLINICAL OPHTHALMOLOGY. 2016;10:1187-1197 | 29.00 | YR | F | Y | 0.00000 | 20160902 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127098772 | 12709877 | 1 | SS | BRIMONIDINE | BRIMONIDINE TARTRATE | 1 | Ophthalmic | 0 | |||||||||||
127098772 | 12709877 | 2 | PS | DORZOLAMIDE,TIMOLOL | DORZOLAMIDETIMOLOL | 1 | Ophthalmic | 78749 | EYE DROPS NOS | ||||||||||
127098772 | 12709877 | 3 | SS | LATANOPROST. | LATANOPROST | 1 | Ophthalmic | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127098772 | 12709877 | 1 | Glaucoma |
127098772 | 12709877 | 2 | Glaucoma |
127098772 | 12709877 | 3 | Glaucoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127098772 | 12709877 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127098772 | 12709877 | Condition aggravated | |
127098772 | 12709877 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |